Skip to main content Back to Top
Advertisement

9/15/2017

Methylphenidate Hydrochloride Chewable Tablets

Products Affected - Description

    • Methylin chewable tablet, Shionogi Pharma, 10 mg, 100 count, NDC 59630-0762-10
    • Methylin chewable tablet, Shionogi Pharma, 2.5 mg, 100 count, NDC 59630-0760-10
    • Methylin chewable tablet, Shionogi Pharma, 5 mg, 100 count, NDC 59630-0761-10

Reason for the Shortage

    • Shionogi Pharma discontinued Methylin chewable tablets in July 2017.
    • Gavis launched methylphenidate chewable tablets in April 2015.

Available Products

    • Methylphenidate Hydrochloride chewable tablet, Gavis Pharmaceuticals, 10 mg, 100 count, NDC 43386-0572-01
    • Methylphenidate Hydrochloride chewable tablet, Gavis Pharmaceuticals, 2.5 mg, 100 count, NDC 43386-0570-01
    • Methylphenidate Hydrochloride chewable tablet, Gavis Pharmaceuticals, 5 mg, 100 count, NDC 43386-0571-01

Estimated Resupply Dates

    • All presentations are readily available.

Updated

Updated September 15, 2017 by Elyse MacDonald, PharmD, MS, BCPS. Created March 8, 2011 by Jane Chandramouli, PharmD, Drug Information Specialist. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.
ADVERTISEMENT